JasonCChandlerMD

Oncology • Germantown, TN

Assistant Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine

Join to view full profile

Dr. Chandler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chandler's full profile

Already have an account?

Office
7945 Wolf River Blvd
Germantown, TN 38138
Phone+1 901-683-0055

Fax+1 901-922-6701

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2009
University of TennesseeResidency, Internal Medicine/Pediatrics, 2003 - 2007
University of Tennessee Health Science Center College of MedicineClass of 2003

Certifications & Licensure

MS State Medical License 2010 - 2025
TN State Medical License 2006 - 2025
AR State Medical License 2012 - 2024
OH State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017

Clinical Trials

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3

Publications & Presentations

PubMed

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Andres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, Abraham S Kanate, Michelle Quinlan
Clinical Pharmacology in Drug Development. 2022-09-01
5 citations
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Vincent Ribrag, Julio C Chavez, Carola Boccomini, Jason Kaplan, Jason C Chandler
Ejhaem. 2022-02-01
29 citations
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...
Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster
The Lancet. Haematology. 2021-04-01

Press Mentions

World-Renowned Cancer Experts to Speak at the West Oncology Conference in MemphisDecember 26th, 2022
West Cancer Center & Research Institute Specialists Featured at Prestigious Oncology EventJune 13th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member